Pulmonx Co. (NASDAQ:LUNG) Receives $13.36 Average PT from Analysts

Pulmonx Co. (NASDAQ:LUNG) has earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $13.36.

Several research firms have issued reports on LUNG. Jefferies Financial Group assumed coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a “buy” rating for the company. D. Boral Capital initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They set a “buy” rating and a $17.00 target price on the stock. Citigroup began coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating for the company. Wells Fargo & Company reduced their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, Morgan Stanley assumed coverage on Pulmonx in a research report on Monday, March 10th. They issued an “equal weight” rating for the company.

Insider Activity

In other Pulmonx news, insider Geoffrey Beran Rose sold 5,779 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now directly owns 285,278 shares of the company’s stock, valued at $2,034,032.14. This represents a 1.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Glendon E. French III sold 55,453 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the sale, the director now directly owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. The trade was a 5.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 147,986 shares of company stock worth $1,143,673 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Pulmonx during the third quarter worth about $480,000. Charles Schwab Investment Management Inc. grew its position in shares of Pulmonx by 5.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock worth $2,596,000 after acquiring an additional 15,543 shares in the last quarter. FMR LLC increased its holdings in shares of Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after acquiring an additional 591,859 shares during the last quarter. PDT Partners LLC increased its holdings in shares of Pulmonx by 25.3% in the 3rd quarter. PDT Partners LLC now owns 88,074 shares of the company’s stock valued at $730,000 after acquiring an additional 17,784 shares during the last quarter. Finally, PFM Health Sciences LP acquired a new stake in shares of Pulmonx during the 3rd quarter valued at approximately $3,058,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Trading Up 2.1 %

Shares of LUNG opened at $6.87 on Friday. The stock’s fifty day simple moving average is $7.19 and its 200 day simple moving average is $6.93. Pulmonx has a twelve month low of $5.46 and a twelve month high of $10.01. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $273.40 million, a P/E ratio of -4.77 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The company had revenue of $23.77 million for the quarter, compared to the consensus estimate of $22.29 million. On average, equities research analysts forecast that Pulmonx will post -1.55 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.